Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top and bottom lines, with revenue at $0 vs. $0.94M expected and GAAP EPS of -$1.11 vs. -$1.16 expected. While the net loss widened YoY to $110.7M due to intensified Phase 3 clinical activity for azetukalner, the loss per share was slightly better than the mean estimate due to a significantly higher share count from recent financing. Crucially, management confirmed the NDA submission for azetukalner remains on track for Q3 2026, backed by a robust $1.2B cash position extending the runway into 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Xenon Pharma(XENE) the Revenue is 0 (--%), Miss estimate;the EBIT is -123.16 M (-30.7%), Miss estimate;the EPS is -1.11 (-3.74%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.00B--
-0.00B--%
EBITMiss expectations
-0.12B30.70%
-0.11B19.46%
-0.01B11.24%
EPSExceed expectations
-1.113.74%
-1.16168.56%
+0.05164.82%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf